Low-dose rituximab as induction therapy for ANCA-associated vasculitis
Low-dose rituximab as induction therapy for ANCA-associated vasculitis
About this item
Full title
Author / Creator
Publisher
London: Springer London
Journal title
Language
English
Formats
Publication information
Publisher
London: Springer London
Subjects
More information
Scope and Contents
Contents
Administration of four once-weekly doses of 375 mg/m
2
rituximab (RTX) is commonly used as remission induction therapy for ANCA-associated vasculitis (AAV). Low-dose RTX has been recently shown to produce closely similar results to conventional treatments in other autoimmune diseases. However, the therapeutic potential of this approach in AAV...
Alternative Titles
Full title
Low-dose rituximab as induction therapy for ANCA-associated vasculitis
Authors, Artists and Contributors
Identifiers
Primary Identifiers
Record Identifier
TN_cdi_proquest_journals_2170790152
Permalink
https://devfeature-collection.sl.nsw.gov.au/record/TN_cdi_proquest_journals_2170790152
Other Identifiers
ISSN
0770-3198
E-ISSN
1434-9949
DOI
10.1007/s10067-019-04443-2
